Should You Climb on Board the Corcept Therapeutics Train?

Corcept Therapeutics Inc. (NASDAQ: CORT) continues to make its investors happy. The Menlo Park, Calif., biotech company beat earnings estimates in its first-quarter report last week. Revenue for the quarter was $93.2 million, an increase of 44% from the same quarter last year. While the effects of the COVID-19 pandemic have led some companies to forgo guidance, Corcept reaffirmed its revenue estimates of $355 million to $375 million for the year. 

IMAGE SOURCE: GETTY IMAGES

The company has a well-defined mission and performs it well, developing drugs to treat metabolic, oncologic, and psychiatric disorders by regulating the effects of the stress hormone cortisol. Cortisol is known as the "fight or flight" hormone, and it's needed for several basic body functions.

Continue reading

Source Fool.com